Setting 
My Cart
Toggle Nav
Close
  • Menu
  • Setting

SB202190 (FHPI)

Catalog No.
A1632
MAPK inhibitor
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$94.00
In stock
100mg
$84.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

SB 202190 (CAS 152121-30-7) is a cell-permeable pyridinyl imidazole compound, functioning as a selective inhibitor of p38α and p38β2 mitogen-activated protein kinases (MAPKs) and exhibiting inhibitory activity against these enzymes in signal transduction pathways. Additionally, it binds to the ATP pocket of recombinant human active p38 kinase, interfering with downstream cellular signaling.

In in vitro biochemical assays, SB 202190 effectively blocks the phosphorylation of substrate proteins with an IC50 value of 50 nM for p38α and 100 nM for p38β2, tested against recombinant human kinases. It can also bind to the ATP-binding domain of p38 MAPK with a Kd value of 38 nM. SB 202190 has been observed to inhibit the activation of p38-dependent transcription factors and reduce the expression of pro-inflammatory cytokines in cultured cells. Furthermore, in cellular contexts, SB 202190 modulates cellular proliferation, promotes apoptosis in certain cancer cell lines, and affects memory-associated signaling pathways.

In research and preclinical application, SB 202190 is widely used for studies of MAPK signaling, investigation of inflammatory processes, and exploration of cancer therapeutics. It serves as a valuable tool for elucidating the role of p38 MAPK in cellular responses and disease models.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt331.34
Cas No.152121-30-7
FormulaC20H14N3OF
SynonymsSB 202190
Solubilityinsoluble in H2O; ≥22.47 mg/mL in EtOH; ≥57.7 mg/mL in DMSO
Chemical Name4-(4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)phenol
SDFDownload SDF
Canonical SMILESOc(cc1)ccc1-c1nc(-c(cc2)ccc2F)c(-c2ccncc2)[nH]1
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment[1]:

Cell lines

THP-1 and MV4-11 leukemia cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Reacting condition

72 h, 5 μM

Applications

SB202190 is a specific inhibitor of p38ɑ and p38β through competition with ATP for the same binding site on p38. SB202190 potently activated the growth of THP-1 and MV4-11 cells. Furthermore, SB202190 increased the phosphorylation of C-Raf and ERK, suggesting that Raf–MEK–MAPK pathway activation is involved in the cell growth induced by SB202190.

Animal experiment [2]:

Animal models

Three-month specific pathogen-free (SPF) male Wistar rats

Dosage form

5 μL of 10 μmol/L SB202190, ICV injection

Application

One week after SB202190 treatment, p38 MAPK phosphorylation in hippocampus was higher in the model group than in the SB202190 group. Compared to the model group, the SB202190 group exhibited significantly shorter escape latencies in the Morris water maze hidden platform trials. The SB202190 group also showed higher Bcl-2 expression, lower caspase-3 expression and significantly decreased neuronal apoptosis in hippocampus.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Hirosawa M, Nakahara M, Otosaka R, et al. The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells [J]. Leukemia research, 2009, 33 (5): 693-699.

[2] Yang S, Zhou G, Liu H, et al. Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia [J]. BioMed research international, 2013, 2013: 215798.

Biological Activity

Description SB202190 is a highly selective, potent and cell-permeable inhibitor of p38 MAP kinases with IC50 values of 50 nM and 100 nM for p38α and p38β, respectively.
Targets p38α MAPK p38β MAPK        
IC50 50 nM 100 nM        

Quality Control